Zika vaccine candidates progress through nonclinical development and enter clinical trials

npj Vaccines

Volumn 1, Issue , 2016, Pages

  Barrett, Alan Dt ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85017439055     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/npjvaccines.2016.23     Document Type: Review

References (24)

1. Dawes, B. E. et al. Research and development of Zika virus vaccines. npj Vaccines 1, 16007 (2016).
2. Durbin, A. P. Vaccine development for Zika virus-Timelines and strategies. Semin. Reprod. Med. 34, 299-304 (2016).
3. Pierson, T. C. & Graham, B. S. Zika virus: immunity and vaccine development. Cell 167, 625-631 (2016).
4. Martins, K. A., Dye, J. M. & Bavari, S. Considerations for the development of Zika virus vaccines. Vaccine 34, 3711-3712 (2016).
5. Marston, H. D., Lurie, N., Borio, L. L. & Fauci, A. S. Considerations for developing a Zika virus vaccine. N. Engl. J. Med. 375, 1209-1212 (2016).
6. Palacios, R., Poland, G. A. & Kalil, J. Another emerging arbovirus, another emerging vaccine: Targeting Zika virus. Vaccine 34, 2291-2293 (2016).
7. Plotkin, S. A. Zika as still another argument for a new path to vaccine development. Clin. Microbiol. Infect. 22, 294-295 (2016).
8. Tripp, R. A. & Ross, T. M. Development of a Zika vaccine. Expert Rev. Vaccines. 15, 1083-1085 (2016).
9. Thomas, S. J., L'Azou, M., Barrett, A. D. & Jackson, N. A. Fast-Track Zika vaccine development-is it possible? N. Engl.J. Med. 375, 1212-1216 (2016).
10. Shan, C. et al. Zika virus: diagnosis, therapeutics, and vaccine. ACS Infect. Dis 2, 170-172 (2016).
11. Vannice, K. S. et al.Meeting Report:WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. Vaccine, in press.
12. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474-478 (2016).
13. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129-1132 (2016).
14. Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237-240 (2016).
15. Kim, E. et al. Preventive vaccines for Zika virus outbreak: preliminary evaluation. EbioMedicine, Epub ahead of print: 3 October 2016.
16. Muthumani, K. et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody. npj Vaccines http:/dx.doi.org/10.1038/NPJVACCINES. 2016.21 (2016).
17. Van Gessel, Y. et al. Correlation of protection against JE vaccine IXIARO induced neutralizing antibody titers. Vaccine 29, 5925-5931 (2011).
18. Kostyuchenko, V. A. et al. Structure of the thermally stable Zika virus. Nature 533, 425-428 (2016).
19. Sirohi, D. et al. The 3.8 QÅ resolution cryo-EM structure of Zika virus. Science 352, 467-470 (2016).
20. Goo, L. et al. (2016) Zika virus is not uniquely stable at physiological temperatures compared to other flaviviruses. MBio. 6, 5 (2016).
21. Zhao H, et al. Structural basis of zika virus-specific antibody protection. Cell. 166. 1016-1027. 2016
22. Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823-826 (2016).
23. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48-53 (2016).
24. Dai, L. et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19, 696-704 (2016)